Receiving Adjuvant Trastuzumab. A randomized double-blind, placebocontrolled
|
|
|
- Stephanie Moody
- 6 years ago
- Views:
Transcription
1 DST Study Protocol acronym Study Title Site Status Detail Determining the Cardiac Biomarker Profile in Breast Cancer Patients Cardiac Biomarker Receiving Adjuvant Trastuzumab Breast (Cabot) CABOT Therapy Feasibility Study of the Role of Stereotactic Body Radiotherapy for the Treatment of Early Stage Breast Breast CK Breast Study ARTEMIS Breast CLEE011A2301 (MONALEESA-2) MONALEESA-2 Clinicaltrials.gov number Cancer A randomized double-blind, placebocontrolled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2- negative, advanced breast cancer who received no prior therapy for advanced disease NCT Breast IND.213 Breast LEGACY Breast MAC.15 (S1007) Breast MELO-D MELO-D Breast OCOG-2011-PETRA PETRA A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer NCT Establishment of a cohort of girls in breast cancer families The Ontario LEGACY Pilot Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer NCT Anti-Proliferation Effects of Vitamin D and Melatonin in Breast Cancer NCT Imaging With 111 Indium (111In)- Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) (PETRA) NCT
2 Breast OCOG-2012-LUMINA LUMINA Breast ONCOTYPE DX (BIANCO) Breast RTOG 1119 A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer (LUMINA) NCT A Prospective Cohort Study to Evaluate the Oncotype DX Test in Early Stage Breast Cancer (sub study) Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer NCT GI BO25114 JACOB GI CO.21 CHALLENGE A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating The Efficacy And Safety Of Pertuzumab In Combination With Trastuzumab And Chemotherapy In Patients With Her2-Positive Advanced Gastric Cancer NCT A Phase III Study of the Impact of a Physical Activity Program on Disease- Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) NCT GI GI CRC.6 NEC.3 A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer NCT Prospective Randomized Phase II Trial of Pazopanib (NSC # , IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors NCT
3 GI PA.6 (PRODIGE) ACCORD GI RTOG 1112 AGS15E-13-1 Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mfolfirinox) in Patients With Resected Pancreatic Adenocarcinoma NCT Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer NCT A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer NCT BL.12 Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advance Urothelial Cancer Progressing on or After Platinum Containing Regimen. NCT IMRT_ISD_JARES Randomized Study of Quality of Life in Patients with High-Risk Prostate Cancer Undergoing Radiotherapy: Role of Pelvic Nodal IMRT IND.209 Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer NCT
4 NCRN BAYER Radium223 in subjects with bone predominant metastatic CRPC OZM-042 OZM-053 PREVAIL Open Label Extension (OLE) A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC) A Phase II, Multi-Centre, Study of the Efficacy and Safety of Sunitinib Given on an Individualized Schedule as First- Line Therapy for Metastatic Renal Cell Cancer. NCT A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo- Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy NCT A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) - Open Label Extention (OLE) NCT RTOG 0534:Phase III PELVIC RTOG 0815 Prostate Radiation Therapy or Short- Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer NCT Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer NCT
5 GYNE SPARTAN (Selective Prostate AR Targeting with ARN-509) ARRAY :The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) SPARTAN MILO SPARTAN - A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase III Study of ARN- 509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer A Multinational, Randomized, Openlabel Phase 3 Study of MEK162 vs. Physician s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum NCT GYNE Brachytherapy-Rectal Retraction GYNE CO (ARIEL3) ARIEL 3 GYNE GYNE PHL-085:recurrent /metastatic HPV related PHL-086 PHL085 Dosimetric Comparison of Rectal Retraction Methods in Brachytherapy for Cervical Carcinoma A Multicenter, Randomized, Double- Blind, Placebo-Controlled Phase 3 Study of Rucaparib as witch Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, Relapsed High-Grade Serous Ovarian Cancer(ARIEL3) NCT A Phase 2 Study of Ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma of either squamous cell or adenocarcinoma histologies NCT A Study of XL184 (Cabozantinib) in Endometrial Cancer NCT GYNE PR C (NOVA) A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer NCT
6 GYNE RTOG 1174 (OUTBACK) OUTBACK GYNE RTOG 1203 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial NCT Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer NCT Head&Neck Head&Neck Head&Neck CBKM120H2201:Study of Efficacy and Safety of Buparlisib (BKM120) MU ALTENS for Dysphagia: A Pilot Study of ALTENS in Improving Dysphagia Induced by IMRT for Head and Neck Cancers PHL-088:Cisplatin With or Without MK-1775 in Squamous Cell Cancer of the Head and Neck PHL 088 Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) NCT Effectiveness of Acupuncture-like Transcutaneous Nerve Stimulation (ALTENS) in Improving Dysphagla and Associated Symptoms of Current Chemotherapy and IMRT for Head and Neck Cancers: A Pilot Study NCT A Randomized Phase II Trial of Cisplatin with or without Wee1 kinase inhibitor MK-1775 for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN) NCT Head&Neck VOICE Voice Quality Assessment Following External Beam Radiotherapy for T1 Laryngeal Cancer
7 Hematology B A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT Hematology C16014(Millenium ) Hematology CICL670A2421:Combinati on Study of Deferasirox and Erythropoietin in Patients With Low- and Int- 1-risk Myelodysplastic Syndrome. KALLISTO A Phase 3, Randomized, Double- Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma NCT An open-label, phase II, randomized, pilot study to assess the effect in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with low- and int-1-risk myelodysplastic syndrome. NCT Hematology Hematology Hematology A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Postpolycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib NCT GS-US MEDICATE - Cardiac Troponin Study MEDICATE - Cardiac Troponin Study NCRN GDC-0199 in CLL (GO28667) - MURANO A multicentre, phase III, open label randomised study in relapsed/refractory patients with chronic lymphocytic leukaemia to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab NCT
8 Hematology Hematology NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC) NCRN529 SHINE: Ibrutinib + BR in newly diagnosed mantle cell AZA-MDS-003 A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusiondependent anemia and thrombocytopenia due to IPSS lowerrisk myelodysplatic syndromes NCT lymphoma SHINE NCT A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell BR.31 Cancer. NCT C14018 A Randomized, Double-blind, Placebocontrolled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Cancer (SCLC) NCT IND.211 IND.215:Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC IND.215 A Randomized Phase II Study Of Reolysin In Patients With Previously Treated Advanced Or Metastatic, Non Small Cell Cancer Receiving Standard Salvage Therapy NCT A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens. NCT
9 NCRN VESTA: Veliparib, carboplatin & paclitaxel in NSCLC M OCOG-2011-BRACHY Brachy OCOG-2013-LUSTRE OCOG-2014-ALMERA ALMERA NSCLC M11089 A Phase 3 Veliparib plus Chemotherapy Study in Adv/Met squamous NSCLC A Trial to Evaluate the Improvement in Cancer Patients Receiving Radiation With or Without Brachytherapy (BRACHY) NCT A Randomized Trial of Medically- Inoperable Stage I Non-Small Cell Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy (LUSTRE) NCT A Phase II Study to Investigate a Combination of Metformin with Chemo- Radiotherapy in Patients with Locally Advanced Non-Small Cell Cancer Advanced Cancer TIDAL Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non- Small Cell Cancer (TIDAL) NCT Melanoma BRF COMBI-MB Melanoma Neuro Neuro OZM-049/TH-CR-413 CEC.1 (RTOG 0834; EORTC ) CEC.3/N107C BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain NCT A Phase 2 Biomarker-Enriched Study of TH-302 in Subjects with Advanced Melanoma NCT Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma. NCT A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease NCT
10 Neuro EF-14:Effect of NovoTTF- 100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) EF-14 Neuro SABR-COMET SABR-COMET Other PHL-072 PHL072 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM NCT Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR- COMET): A Randomized Phase II Trial NCT A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer NCT Other Other PROUD Study (PAL- ABST-401) RTOG 0631:Phase II/III Radiosurg for spine METs PROUD/Abstral Program Abstral Drug Utilization Study - Observational Study Evaluating "Real World" Utilization of Abstral in Canada Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis NCT Phase I BAY /16653 A Phase I, multi-center, nonrandomized, open label, parallel-group study evaluating the pharmacokinetics and safety of regorafenib (BAY ) in cancer subjects with severe renal impairment compared to a control group NCT Phase I BAY / An open-label, non-randomized, Phase I study to evaluate the effect of itraconazole on the pharmacokinetics of a single intravenous dose of copanlisib in patients with advanced solid tumors
11 Phase I BI An open label phase I dose finding study of BI administered orally in a continuous dosing schedule in patients with various advanced or metastatic non-hematologic malignancies NCT Phase I Phase I Sarcoma Sarcoma CPD-1028 IND.214 AB04030 AB11002 A Phase 1a, multi-centre, open-label, non-randomized study to assess the safety, biodistribution and tumour uptake of [I-124]-CPD-1028 Injection NCT A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3- Expressing Solid Tumours NCT A prospective, multicenter, randomized, open-label, activecontrolled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment NCT A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib NCT
Page 1 of 9 printed on 06 May 2015
Sarcoma ALDOXORUBICIN-P-3-STS-01 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator s Choice in Subjects with Metastatic,
Open NCT NCT Open NCT
Updated Feb 18/16. Please note, although every effort is made to keep this list as up-to-date as possible, some trial status updates may not be reflected in the list below. DST Project Title Project Display
List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number
Breast Cardiac Biomarker (Cabot) CABOT Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy Breast IND.213 A Study of Reolysin For Patients With Advanced/Metastatic
List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number
Breast ALTENS(Hot Flash Study) Hot Flash Study A Phase II Study of Acupuncture-like trancutaneous electrical nerve stimulation in the management of vasomotor symptoms induced by breast cancer treatments.
List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number
Breast ALTENS(Hot Flash Study) Hot Flash Study A Phase II Study of Acupuncture-like trancutaneous electrical nerve stimulation in the management of vasomotor symptoms induced by breast cancer treatments.
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
Title Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
All Studies by Indication
Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
Open clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
Open clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
CLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
Etudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination
Conflict of Interest All Trials NOT Permanently Closed (as of February 2, 2017)
BRAIN Conflict of Interest All Trials NOT Permanently Closed (as of February 2, 2017) CE2 CE5 CEC1 CEC2 CEC3 Phase III Intergroup Randomized Comparison of Radiation Alone versus Preradiation Chemotherapy
Etudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer
CancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of
MEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship
CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous
Conflict of Interest All Trials NOT Permanently Closed (as of January 10, 2018)
TRIAL BRAIN Conflict of Interest All Trials NOT Permanently Closed (as of January 10, 2018) NAME TRIAL STATUS TRIAL TYPE NCI US- Affiliated (Yes or No) Company/ Commercial entity CE2 CE5 CE5S CE7 CE8 CEC1
Summary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished
No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date No of patients recruited
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013
N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013 Bladder HABIO Haematuria Biomarker Study Bowel Cancer NSCCG National Study Of Colorectal Cancer Genetics
The Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
Performance in Initiating Clinical Research Q2 2016/17
Performance in Initiating Clinical Research Q2 2016/17 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS
Open clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
HRA Approval Date Site Date Site Sponsor. Non- Confirmation Status. Date Site Ready To Start
Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial Date of Receipt of Date of Valid Research Application First Patient Recruited? Date
6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
Date Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed
Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial First Patient Recruited? Date of First Patient Recruited Invited Selected Approval
The Clinical Research E-News
Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating
Studienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
The Clinical Research E-News
Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal
Etudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Mars 2017 SEIN ADJUVANT OLYMPIA : A Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant therapy in BRCA mutated
Clinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat
Clinical Research in Rare Cancers Friday 10 th February 2012 Matt Seymour & Nicola Keat Rare cancer is a common disease Rare Cancer : [prevalence
Studies proceeding under pre HRA-Approval system (NHS Permission)
15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL
OPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
Open clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
Performance in Initiating Clinical Research Q4 2015/16
Performance in Initiating Clinical Research Q4 2015/16 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application
CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)
CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered
PROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
The Clinical Research E-News
Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized
Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
Supplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
Currently recruiting trials and/or near future recruitment
Clinical Trials at the Bank of Cyprus Oncology Centre (As of Jan 2018) Currently recruiting trials and/or near future recruitment Development of a module to supplement the EORTC Core instruments for assessment
For Health Professionals Who Care For Cancer Patients
April 2018 Volume 21, No. 4 For Health Professionals Who Care For Cancer Patients Inside This Issue: Editor s Choice New Programs: Palbociclib for Metastatic Breast Cancer, Adjuvant Capecitabine for Breast
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
Aisha Ahmed M.D Cell: (306)
Aisha Ahmed M.D Cell: (306) 450-2292 Email:draisha_80@yahoo.com Academic Appointments Clinical Assistant Professor 6/2014 - Present Department of Medicine University of Saskatchewan. Canada Current Position
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
Cancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
Paediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies. Open. In Development. In Development. Open. Open.
Paediatric Cancer Brain LGG2: Cooperative multicenter study for children and adolescents with Low Grade Glioma GD2: A Phase I/II dose schdule finding study of CH14.18/CHO continuous infusion combined wugt
Open Trials as of end of March 2016
EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG
CancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
Date of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date
14/LO/0259 134883 RE-AKT: A randomised Phase II study of enzalutamide (MDV3100) in combination with AZD5363 in s with Metastatic Castration - Resistant Prostate Cancer Yes 08/01/2018 01/07/2016 01/07/2017
Open clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
CancerPACTtm. Cancer Patients Alliance for Clinical Trials. Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011
CancerPACTtm Cancer Patients Alliance for Clinical Trials Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011 Solid Tumors 1. Breast... 2 2. Central Nervous System... 4 3. Gastrointestinal...
Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
It is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)
Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed
GI ONCOLOGY CLINICAL TRIALS AT UCDAVIS
G ONCOLOGY CLNCAL TRALS AT UCDAVS Version: DECEMBER 2017 Please contact us with any questions or any potential clinical patients Edward Kim, MD/PhD email: jhkim@ucdavis.edu pager: 916-816-4059 May Cho,
Target date to recruit patients agreed? Target range. maximum. minimum. Date. 5 Agreed 26/01/ /11/2015 Recruitment Finished.
No REC Reference IRAS No Title Target number of agreed? Target range minimum Target range maximum Target date to recruit agreed? Planned Recruitment end date Total no of recruited at the agreed target
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
The Clinical Research E-News
Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at
Roche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
Roche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
The Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
Click on the tumor site to find open trials at the Cross Cancer Institute
Click on the tumor site to find open trials at the Cross Cancer Institute Breast Melanoma Updated GI Oncologic Imaging Oct 2014 GU Palliative Gyne Pediatric Radiation Oncology H & N Phase I Hematology
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
National Cancer Drugs Fund List Ver4.0
National Cancer Drugs Fund List Ver4.0 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Contro VersDate Revision summary Ver 19 Mar 201 Update following Mar-14
Clinical Trials OPEN to ENROLLMENT
CNS 2014 Second Quarter Clinical Trials OPEN to ENROLLMENT GAB 101 (CNS THERAPEUTICS INC): Safety of 3 mg/ml Gablofen (baclofen injection) Delivered by Intrathecal Administration Using the Synchromed II
JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2014
JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2014 15 years of excellence in patient care, research, and education The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled
Radiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
The Clinical Research E-News
The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials
National Cancer Drugs Fund List Ver4.4
National Cancer Drugs Fund List Ver4.4 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.